Immunohistochemistry biomarker TP53 expression predicts the survival of thymomas.
TP53
Thymomas
surgery
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
19
5
2020
Statut:
ppublish
Résumé
Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear. Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses. A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.
Sections du résumé
BACKGROUND
BACKGROUND
Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.
METHODS
METHODS
Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.
RESULTS
RESULTS
A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60
CONCLUSIONS
CONCLUSIONS
We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.
Identifiants
pubmed: 32420253
doi: 10.21037/gs.2020.03.01
pii: gs-09-02-291
pmc: PMC7225485
doi:
Types de publication
Journal Article
Langues
eng
Pagination
291-299Informations de copyright
2020 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs.2020.03.01). The authors have no conflicts of interest to declare.
Références
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S357-60
pubmed: 20859133
J Thorac Oncol. 2017 Apr;12(4):734-744
pubmed: 28126540
Cell. 2016 Dec 15;167(7):1670-1671
pubmed: 27984715
Ann Surg Oncol. 2016 Feb;23(2):619-25
pubmed: 26474558
J Clin Oncol. 2018 Feb 1;36(4):342-349
pubmed: 29240542
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
Lung Cancer. 2015 Jun;88(3):338-43
pubmed: 25819383
J Clin Oncol. 2007 Apr 20;25(12):1476-81
pubmed: 17442990
Ann Thorac Surg. 2017 Sep;104(3):1047-1053
pubmed: 28619540
Ann Thorac Surg. 2017 May;103(5):e423-e425
pubmed: 28431716
Lancet Oncol. 2015 Feb;16(2):177-86
pubmed: 25592632
J Thorac Dis. 2018 Mar;10(3):1657-1669
pubmed: 29707318
Oncotarget. 2018 Jan 23;9(15):12273-12283
pubmed: 29552309
Cancer Treat Rev. 2018 Dec;71:76-87
pubmed: 30366202
J Thorac Oncol. 2015 Feb;10(2):373-80
pubmed: 25299233
Cancer Cell. 2018 Feb 12;33(2):244-258.e10
pubmed: 29438696
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):321-8
pubmed: 19775829
J Thorac Oncol. 2011 Nov;6(11):1810-7
pubmed: 21964531
Lung Cancer. 2017 Sep;111:59-60
pubmed: 28838398
Ann Thorac Surg. 2017 Nov;104(5):1718-1724
pubmed: 28969896
Lancet. 2000 Aug 26;356(9231):757-61
pubmed: 11085708